Vor Biopharma Inc.
News
Vor Biopharma (NASDAQ:VOR) Will Have To Spend Its Cash Wisely
Simply Wall St There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...\n more…
PureTech Founded Entity Vor Bio Announces New Clinical Data Validating Approach of Using Shielded Transplants to Deliver Targeted Therapies
Business Wire PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) ('PureTech' or the 'Company'), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, noted that...\n more…
New Clinical Data Validates Vor Bio's Approach of Using Shielded Transplants to Deliver Targeted Therapies
Globe Newswire Trem-cel + Mylotarg demonstrated engraftment, shielding, broadened therapeutic window, and patient benefitVCAR33ALLO demonstrates encouraging biomarker data at lowest dose New asset VADC45 with...\n more…
Vor Bio to Participate in Upcoming Investor Conferences
Globe Newswire CAMBRIDGE, Mass., Aug. 28, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that it will participate in the following upcoming...\n more…
VOR Stock Earnings: Vor Biopharma Beats EPS for Q2 2024
InvestorPlace InvestorPlace - Stock Market News, Stock Advice & Trading Tips\nVOR stock results show that Vor Biopharma beat analyst estimates for earnings per share the second quarter of 2024.\nThe post VOR Stock...\n more…
Vor Bio Reports Second Quarter 2024 Financial Results and Provides Company Update
Globe Newswire On-track for trem-cel + Mylotarg and VCAR33ALLO clinical updates in the second half of 2024 CAMBRIDGE, Mass., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and...\n more…